Osteoporosis is a skeletal disorder characterized by compromised bone strength, which
predisposes a person to increased risk of fracture. In the United States, 26% of women …

This article reviews progress in chemopreventive drug development, especially data and
concepts that are new since the 2002 AACR report on treatment and prevention of …

ContextTamoxifen is approved for the reduction of breast cancer risk, and raloxifene has
demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis …

Background The effect of raloxifene, a selective estrogen-receptor modulator, on coronary
heart disease (CHD) and breast cancer is not established. Methods We randomly assigned …

Objectives: In this study, the effects of the Cimicifuga racemosa (CR) preparation CR BNO
1055 on markers of bone metabolism, hormones, sex hormone-binding globulin (SHBG) …

Objective To provide guidelines for the health care provider on the diagnosis and clinical
management of postmenopausal osteoporosis. Outcomes Strategies for identifying and …

Nonsurgical treatment options, such as hormonal therapy, chemotherapy, radiation, and
bisphosphonate therapy, are undoubtedly improving outcomes for women with breast …

Purpose: To assess the effect of raloxifene, indicated for osteoporosis treatment and
prevention, on invasive breast cancer in subgroups of postmenopausal women defined by …

Background: Lifetime estrogen exposure has been related to breast cancer risk,
osteoporosis, and cardiovascular disease but data on venous thromboembolism (VTE) risk …

Osteoporosis and related fractures are a significant concern for the global community. As the
population continues to age, morbidity and mortality from fractures due to low bone mineral …